Video Experimental Relacionado
Updated: Jun 19, 2026
06:43
A Novel In Vitro Live-imaging Assay of Astrocyte-mediated Phagocytosis Using pH Indicator-conjugated Synaptosomes
Published on: February 5, 2018
Regulación metabólica del cerebro Abeta por la neprilysina
1Laboratory for Proteolytic Neuroscience, RIKEN Brain Science Institute, Wako-shi 351-0198 Japan.
Science (New York, N.Y.)
|May 26, 2001
Resumen
La neprilisina, una enzima que degrada el péptido beta amiloide (Abeta), juega un papel crucial en la patología de la enfermedad de Alzheimer (EA). Su deficiencia afecta el aclaramiento de Abeta, lo que sugiere que la disminución de la neprilisina relacionada con el envejecimiento puede impulsar la progresión de la EA.
Área de la Ciencia:
- La neurociencia es la neurociencia.
- La bioquímica es la bioquímica.
- Genética La genética.
Sus antecedentes:
- El péptido beta amiloide (Abeta) está implicado en la patogénesis de la enfermedad de Alzheimer (EA).
- Neprilysin es una enzima potencial responsable de la degradación de Abeta en el cerebro.
Objetivo del estudio:
- Para investigar el papel de la neprilysina en el metabolismo de Abeta.
- Para determinar el impacto de la deficiencia de neprilysina en los niveles de Abeta y la distribución in vivo.
Principales métodos:
- Utilizó ratones con alteración del gen neprilysin para estudiar el metabolismo de Abeta.
- Se administraron Abeta exógeno y se midieron los niveles de Abeta endógeno.
- Se analizó la distribución regional de Abeta en el cerebro de ratón.
Principales resultados:
- La deficiencia de neprilisina afectó tanto a la degradación exógena de Abeta como a la supresión endógena de Abeta de una manera dependiente de la dosis del gen.
- Los niveles regionales de Abeta en ratones con deficiencia de neprilysina siguieron el orden: hipocampo > corteza > tálamo/striato > cerebelo.
- Esta distribución regional se correlacionó con la vulnerabilidad de la deposición de Abeta en los cerebros humanos de AD.
Conclusiones:
- La neprilisina es una enzima clave en la degradación de Abeta.
- La actividad reducida de la neprilisina, potencialmente debido al envejecimiento, puede contribuir a la acumulación de Abeta y al desarrollo de la EA.
- Dirigirse a la neprilysina puede ofrecer una estrategia terapéutica para la enfermedad de Alzheimer.
Videos de Conceptos Relacionados
01:19Allosteric Proteins-ATCase
Binding sites linkages can regulate a protein's function. For example, enzyme activity is often regulated through a feedback mechanism where the end product of the biochemical process serves as an inhibitor.
Aspartate transcarbamoylase (ATCase) is a cytosolic enzyme that catalyzes the condensation of L-aspartate and carbamoyl phosphate to N-carbamoyl-L-aspartate. This reaction is the first step in pyrimidine biosynthesis. UTP and CTP, the end products of the pyrimidine synthesis pathway,...
Aspartate transcarbamoylase (ATCase) is a cytosolic enzyme that catalyzes the condensation of L-aspartate and carbamoyl phosphate to N-carbamoyl-L-aspartate. This reaction is the first step in pyrimidine biosynthesis. UTP and CTP, the end products of the pyrimidine synthesis pathway,...
01:27Transducer Mechanism: Enzyme-Linked Receptors
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
01:21Drugs Affecting Neurotransmitter Release or Uptake
Certain drugs can affect how neurotransmitters called catecholamines, are released or taken back up in the adrenergic neuron. They can have different effects on the body's sympathetic transmission. Reserpine, a natural compound found in the Rauwolfia shrub, blocks a transporter called vesicular monoamine transporter (VMAT), which leads to a buildup of catecholamines in the cell and reduces sympathetic transmission. Another drug called guanethidine works in multiple ways, including blocking...
01:29Drugs Affecting Neurotransmitter Synthesis
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase, which converts...
01:24Phase II Reactions: Acetylation Reactions
Acetylation, a phase II biotransformation reaction, introduces an acetyl group to drugs or their metabolites. Acetyltransferase enzymes facilitate this reaction, which resembles α-amino acid conjugation due to the addition of a functional group to the drug molecule.
The substrates for acetylation are typically drugs or their metabolites with an amino, sulfonamide, or hydrazine functional group. Acetylation can occur at several points in the drug molecule, including primary, secondary, and...
The substrates for acetylation are typically drugs or their metabolites with an amino, sulfonamide, or hydrazine functional group. Acetylation can occur at several points in the drug molecule, including primary, secondary, and...
01:29Hepatic Encephalopathy
DefinitionHepatic encephalopathy is a reversible neurologic syndrome that results from advanced liver dysfunction or portosystemic shunting. It leads to disturbances in cognition, behavior, and motor function due to the brain’s exposure to gut-derived toxins that the liver fails to detoxify.EtiologyThis condition develops either in the setting of acute fulminant hepatitis or progressively during chronic liver disease, such as cirrhosis and portal hypertension. Portosystemic shunting—including...